

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

cant: Jacob Bar-Tana

Serial No.: 10/735,439 Examiner: L.A. Royds

Filed: December 11, 2003 Art Unit: 1614

FOR : METHODS FOR THE TREATMENT OF SYNDROME X USING

XENOBIOTIC FATTY ACID COMPOUNDS

1185 Avenue of the Americas New York, New York 10036 November 27, 2007

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## AMENDMENT IN RESPONSE TO FEBRUARY 23, 2007 FINAL OFFICE ACTION AS A SUBMISSION UNDER 37 C.F.R. §1.114(C), PETITION FOR A TWO-MONTH EXTENSION OF TIME AND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Amendment is submitted in response to the February 23, 2007 Final Office Action issued by the U.S. Patent and Trademark Office in connection with the above-identified application. Applicants are concurrently submitting a Request For Continued Examination (RCE). Accordingly, this Amendment is filed as a submission under 37 C.F.R. §1.114(c) accompanying an RCE. response to the February 23, 2007 Final Office Action was due May 23, 2007. On August 23, 2007, applicant mailed to the Patent Office a Notice of Appeal And Petition For Three-Month Extension Of Time which was received by the U.S. Patent Office on August 2007. As a result, an appeal brief was initially due September 27, 2007. Applicant hereby petitions for a two-month extension of time. The fee for a two-month extension of time for a small entity is TWO HUNDRED AND THIRTY DOLLARS (\$230.00) and a check including this amount is enclosed. With a two-month extension of time, the deadline for filing an appeal brief or taking other action is November 27, 2007. Accordingly, the RCE and this Amendment filed as a submission with the RCE are being timely filed.

12/03/2007 SSITHIB1 00000022 10735439

02 FC:1806 180.00 OP

12/03/2007 SSITHIB1 00000022 10735439

03 FC:2252 230.00 OP

Applicant: Jacob Bar-Tana Serial No.: 10/735,439 Filed: December 11, 2003

Page 2

Please amend the subject application as follows:

Amendments to the claims begin on page 3 of this paper.

Remarks begin on page 11 of this paper.

A Supplemental Information Disclosure Statement begins on page 22 of this paper.